{"nctId":"NCT04684238","briefTitle":"Effect & Safety of Inhaled Isoflurane vs IV Midazolam for Sedation in Mechanically Ventilated Children 3-17 Years Old","startDateStruct":{"date":"2021-01-14","type":"ACTUAL"},"conditions":["Sedation"],"count":94,"armGroups":[{"label":"Drug: Midazolam","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Midazolam"]},{"label":"Drug: Isoflurane","type":"EXPERIMENTAL","interventionNames":["Drug: Isoflurane"]}],"interventions":[{"name":"Midazolam","otherNames":[]},{"name":"Isoflurane","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients at least 3 years to 17 (less than 18) years at the time of randomization, admitted to an ICU/with planned ICU admission.\n* Expected mechanical (invasive) ventilation and sedation for at least 12 hours.\n* Informed consent obtained from the patient, patient's legal guardian(s)\n\nExclusion Criteria:\n\n* Ongoing seizures requiring acute treatment.\n* Continuous sedation for more than 72 hours at time of randomization.\n* Less than 24 hours post cardiopulmonary resuscitation.\n* Uncompensated circulatory shock.\n* Known or suspected genetic susceptibility to malignant hyperthermia.\n* Patients with acute asthma or obstructive lung disease symptoms requiring treatment at inclusion.\n* Patient with tidal volume below 30 mL or above 800 mL.\n* Inability to perform reliable COMFORT-B assessment in the opinion of the Investigator\n* Patients with intracranial pressure (ICP) monitoring or with suspected increase in ICP\n* Patients with treatment-induced whole-body hypothermia.\n* Patients with pheochromocytoma.\n* Patients with prolonged QT interval or with significant risk for prolonged QT interval.\n* Patient not expected to survive next 48 hours or not committed to full medical care.","healthyVolunteers":false,"sex":"ALL","minimumAge":"3 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Time of Adequately Maintained Sedation Depth up to 48 Hours (± 6 Hours)","description":"Percentage of time of adequately maintained sedation within the COMFORT-B interval (light, moderate or deep sedation) prescribed at randomisation, monitored every 2 h for a minimum of 12 h (up to 48 h ± 6 h)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62.37","spread":null},{"groupId":"OG001","value":"68.94","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Time of Adequately Maintained Sedation Depth up to 48 Hours (± 6 Hours)","description":"Percentage of time of adequately maintained sedation within the COMFORT-B interval (light, moderate or deep sedation) prescribed at randomisation, monitored every 2 h for a minimum of 12 h (up to 48 h ± 6 h)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65.57","spread":null},{"groupId":"OG001","value":"70.91","spread":null}]}]}]},{"type":"SECONDARY","title":"Compare the Use of Opioids","description":"Dose of opioids from first blinded COMFORT-B assessment (at +2 h from start of study drug) to end of study treatment period. This was a key secondary efficacy endpoint. Dose of opioids was expressed as fentanyl IV equivalents.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.6","spread":null},{"groupId":"OG001","value":"2.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Compare the Use of Opioids","description":"Dose of opioids during the last 4 h of study treatment, as compared to the first 4 h of study treatment after first blinded COMFORT-B assessment. This was a key secondary efficacy endpoint. Dose of opioids is expressed as fentanyl IV equivalents.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.58","spread":null},{"groupId":"OG001","value":"-0.19","spread":null}]}]}]},{"type":"SECONDARY","title":"Compare Time From End of Study Drug Administration to Extubation","description":"Time from end of study drug administration to extubation if study drug was terminated for extubation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.09","spread":null},{"groupId":"OG001","value":"0.75","spread":null}]}]}]},{"type":"SECONDARY","title":"Compare the Proportion of Time With Spontaneous Breathing","description":"Proportion of observations with spontaneous breathing efforts during study treatment. This was a key secondary safety endpoint.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.44","spread":null},{"groupId":"OG001","value":"0.48","spread":null}]}]}]},{"type":"SECONDARY","title":"Evaluate Haemodynamic Effect as Indicated by Need for Additional Inotropic/Vasopressor Agent","description":"Need for additional inotropic/vasopressor agent defined by change in Vasoactive-Inotropic Score (VIS) during study treatment period compared to baseline.\n\nThe VIS quantifies the amount of cardiovascular support required by infants postoperatively according to the below calculation:\n\nVIS = dopamine (µg/kg/min) + dobutamine (µg/kg/min) + 100 × epinephrine (µg/kg/min) + 100 × norepinephrine (µg/kg/min) + 10 × milrinone (µg/kg/min) + 10,000 × vasopressin (U/kg/min).\n\nAn increased VIS score correlates to an increase in inotropic/vasopressor agents.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.4","spread":"19.3"},{"groupId":"OG001","value":"3.4","spread":"19.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":"9.7"},{"groupId":"OG001","value":"8.8","spread":"44.4"}]}]}]},{"type":"SECONDARY","title":"Evaluate the Number of Patients With Withdrawal Symptom","description":"Evaluate the frequency of withdrawal symptoms in isoflurane- vs midazolam-treated patients according to SOS-PD.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Evaluate the Frequency of Delirium","description":"Evaluate the frequency of delirium in isoflurane- vs midazolam-treated patients","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]}]},{"type":"SECONDARY","title":"Evaluate the Frequency of Neurological Symptoms or Psychomotor Dysfunction","description":"Evaluate the frequency of neurological symptoms or psychomotor dysfunction during and up to 48 hours after discontinuation of isoflurane and midazolam treatment, and the association with duration of treatment, and total exposure (MAC hours and midazolam doses) over time.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]}]},{"type":"SECONDARY","title":"Compare the 30 Days/Hospital Mortality","description":"Compare the 30 days/hospital mortality in isoflurane- vs midazolam-treated patients","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Compare Ventilator-free Days","description":"Ventilator-free days at 30 days from start of study treatment period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.55","spread":"10.62"},{"groupId":"OG001","value":"25.00","spread":"6.74"}]}]}]},{"type":"SECONDARY","title":"Compare the Time in ICU/Hospital","description":"Compare the time in ICU at 30 days from start of study treatment period. This was a secondary safety endpoint. Patients that were withdrawn prior to day 30 were excluded from the analysis. Patients who died before day 30 were not considered withdrawals. For these patients, the days in ICU until day of death were considered ICU days.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.21","spread":"9.13"},{"groupId":"OG001","value":"9.65","spread":"7.87"}]}]}]},{"type":"SECONDARY","title":"Compare ICU-free Days","description":"Compare ICU-free days up to 30 days in isoflurane- vs midazolam-treated patients.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.58","spread":"10.26"},{"groupId":"OG001","value":"20.35","spread":"7.87"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8,"n":33},"commonTop":["Constipation","Pyrexia","Pleural effusion","Delirium","Bradycardia"]}}}